Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

ClinicalTrials.gov ID: NCT02501902

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02501902. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN OPEN-LABEL PHASE IB STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS ABRAXANE (REGISTERED) (NAB-PACLITAXEL) IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.

Study identification

NCT ID
NCT02501902
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Pfizer
Industry
Enrollment
76 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 23, 2015 (Actual)
Primary completion
Oct 10, 2018 (Actual)
Completion
Dec 27, 2018 (Actual)
Last update posted
Apr 6, 2021

2015 – 2018

United States locations

U.S. sites
21
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
Scottsdale Healthcare Hospitals DBA HonorHealth Scottsdale Arizona 85258 —
Virginia G. Piper Cancer Pharmacy Scottsdale Arizona 85258 —
UC San Diego Medical Center - La Jolla (Thornton Hospital) La Jolla California 92037-0845 —
UC San Diego Moores Cancer Center - Investigational Drug Services La Jolla California 92037-0845 —
UC San Diego Moores Cancer Center La Jolla California 92093 —
UC San Diego Medical Center - Hillcrest San Diego California 92103 —
Anschutz Cancer Pavilion Aurora Colorado 80045 —
University of Colorado Cancer Center Aurora Colorado 80045 —
University of Colorado Denver, CTO (CTRC) Aurora Colorado 80045 —
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) Aurora Colorado 80045 —
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) Aurora Colorado 80045 —
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231-1000 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
Siteman Cancer Center City of Saint Peters Missouri 63376 —
Siteman Cancer Center - West County Creve Coeur Missouri 63141 —
Barnes-Jewish Hospital St Louis Missouri 63110 —
Washington University Infusion Center Pharmacy St Louis Missouri 63110 —
Washington University School of Medicine St Louis Missouri 63110 —
Siteman Cancer Center - South County St Louis Missouri 63129 —
University of Utah, Huntsman Cancer Hospital Salt Lake City Utah 84112 —
University of Utah, Huntsman Cancer Institute Salt Lake City Utah 84112 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02501902, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2021 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.